Slow down to stay alive: HER4 protects against cellular stress and confers chemoresistance in neuroblastoma

Cancer

Volumn 118, Issue 20, 2012, Pages 5140-5154

  Hua, Yingqi ^a,b   Gorshkov, Kirill ^c   Yang, Yanwen ^a   Wang, Wenyi ^a   Zhang, Nianxiang ^a   Hughes, Dennis P M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cellular stress; chemoresistance; HER4 ERBB4; human epidermal growth factor receptor 4; multicellular tumor sphere; neuroblastoma; v erb a erythroblastic leukemia viral oncogene homolog

Indexed keywords

CYCLIN D; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MESSENGER RNA;

ARTICLE; CANCER RESISTANCE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL PROTECTION; CELL STRESS; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; GENE EXPRESSION; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; NEUROBLASTOMA; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84867333911     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27496     Document Type: Article

References (51)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL,. Neuroblastoma. Lancet. 2007; 369: 2106-2120.
2. Hynes NE, Lane HA,. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5: 341-354.
3. Ho R, Minturn JE, Hishiki T, et al. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res. 2005; 65: 9868-9875.
4. Richards KN, Zweidler-McKay PA, Van Roy N, et al. Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer. 2010; 116: 3233-3243.
5. Izycka-Swieszewska E, Wozniak A, Drozynska E, et al. Expression and significance of HER family receptors in neuroblastic tumors. Clin Exp Metastasis. 2011; 28: 1-12.
6. Hughes DP, Thomas DG, Giordano TJ, McDonagh KT, Baker LH,. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer. 2006; 46: 614-623.
7. Pediatric Oncology Branch, Center for Caner Research, National Cancer Institute. Oncogenomics. Available from: http://home.ccr.cancer.gov/oncology/ oncogenomics/ Accessed Nov 18th, 2011.
8. Kang H-G, Jenabi JM, Zhang J, et al. E-cadherin cell-cell adhesion in Ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 2007; 67: 3094-3105.
9. Santini MT, Rainaldi G,. Three-dimensional spheroid model in tumor biology. Pathobiology. 1999; 67: 148-157.
10. Desoize B, Jardillier J,. Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol. 2000; 36 (2-3): 193-207.
11. Olive PL, Durand RE,. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev. 1994; 13: 121-138.
12. Durand RE, Olive PL,. Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. Methods Cell Biol. 2001; 64: 211-233.
13. Bilir A, Erguven M, Yazihan N, Aktas E, Oktem G, Sabanci A,. Enhancement of vinorelbine-induced cytotoxicity and apoptosis by clomipramine and lithium chloride in human neuroblastoma cancer cell line SH-SY5Y. J Neurooncology. 2010; 100: 385-395.
14. Gullick WJ,. c-erbB-4/HER4: friend or foe? J Pathol. 2003; 200: 279-281.
15. Mill CP, Gettinger KL, Riese DJ 2nd,. Ligand stimulation of ErbB4 and a constitutively active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Exp Cell Res. 2011; 317: 392-404.
16. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT,. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 2004; 64: 2047-2053.
17. Hollmen M, Maatta JA, Bald L, Sliwkowski MX, Elenius K,. Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene. 2009; 28: 1309-1319.
18. Naresh A, Long W, Vidal GA, et al. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res. 2006; 66: 6412-6420.
19. Vidal GA, Clark DE, Marrero L, Jones FE,. A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities. Oncogene. 2007; 26: 462-466.
20. Sundvall M, Veikkolainen V, Kurppa K, et al. Cell death or survival promoted by alternative isoforms of ErbB4. Mol Biol Cell. 2010; 21: 4275-4286.
21. Muraoka-Cook RS, Sandahl MA, Strunk KE, et al. ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Mol Cell Biol. 2009; 29: 4935-4948.
22. Elenius K, Corfas G, Paul S, et al. A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J Biol Chem. 1997; 272: 26761-26768.
23. Kainulainen V, Sundvall M, Maatta JA, Santiestevan E, Klagsbrun M, Elenius K,. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem. 2000; 275: 8641-8649.
24. Geryk-Hall M, Yang Y, Hughes DP,. Driven to death: inhibition of farnesylation increases Ras activity in osteosarcoma and promotes growth arrest and cell death. Mol Cancer Ther. 2010; 9: 1111-1119.
25. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DP,. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res. 2008; 14: 2962-2969.
26. Pletnev S, Shcherbo D, Chudakov DM, et al. A crystallographic study of bright far-red fluorescent protein mKate reveals pH-induced cis-trans isomerization of the chromophore. J Biol Chem. 2008; 283: 28980-28987.
27. Lawlor ER, Scheel C, Irving J, Sorensen PH,. Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors. Oncogene. 2002; 21: 307-318.
28. Chen X, Levkowitz G, Tzahar E, et al. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J Biol Chem. 1996; 271: 7620-7629.
29. Linggi B, Carpenter G,. ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional repression. J Biol Chem. 2006; 281: 25373-25380.
30. Jones FE,. HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13: 247-258.
31. Hanahan D, Weinberg Robert A,. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674.
32. Ho JH, Chen YF, Ma WH, Tseng TC, Chen MH, Lee OK,. Cell contact accelerates replicative senescence of human mesenchymal stem cells independent of telomere shortening and p53 activation: roles of Ras and oxidative stress. Cell Transplant. 2011; 20: 1209-1220.
33. Garrido C, Ottavi P, Fromentin A, et al. HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res. 1997; 57: 2661-2667.
34. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA,. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol. 2010; 148: 3-15.
35. Kumar HR, Zhong X, Hoelz DJ, et al. Three-dimensional neuroblastoma cell culture: proteomic analysis between monolayer and multicellular tumor spheroids. Pediatr Surg Int. 2008; 24: 1229-1234.
36. Green SK, Francia G, Isidoro C, Kerbel RS,. Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther. 2004; 3: 149-159.
37. Valcarcel M, Arteta B, Jaureguibeitia A, et al. Three-dimensional growth as multicellular spheroid activates the proangiogenic phenotype of colorectal carcinoma cells via LFA-1-dependent VEGF: implications on hepatic micrometastasis [serial online]. J Transl Med. 2008; 6: 57.
38. Diaz-Montero CM, McIntyre BW,. Acquisition of anoikis resistance in human osteosarcoma cells. Eur J Cancer. 2003; 39: 2395-2402.
39. Douma S, van Laar T, Zevenhoven J, Meuwissen R, van Garderen E, Peeper DS,. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 2004; 430: 1034-1039.
40. Guo D, Han J, Adam B-L, et al. Proteomic analysis of SUMO4 substrates in HEK293 cells under serum starvation-induced stress. Biochem Biophys Res Commun. 2005; 337: 1308-1318.
41. Erlich S, Goldshmit Y, Lupowitz Z, Pinkas-Kramarski R,. ErbB-4 activation inhibits apoptosis in PC12 cells. Neuroscience. 2001; 107: 353-362.
42. 2. Regulation of reactive oxygen species levels by phosphatidylinositol 3-kinase. J Biol Chem. 2001; 276: 46379-46385.
43. Kuramochi Y, Cote GM, Guo X, et al. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1β/erbB4 signaling. J Biol Chem. 2004; 279: 51141-51147.
44. Hollmen M, Elenius K,. Potential of ErbB4 antibodies for cancer therapy. Future Oncol. 2010; 6: 37-53.
45. Sartor CI, Zhou H, Kozlowska E, et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol. 2001; 21: 4265-4275.
46. Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, Elenius K,. Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13: 259-268.
47. Thor AD, Edgerton SM, Jones FE,. Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am J Pathol. 2009; 175: 1802-1809.
48. Gilmore-Hebert M, Ramabhadran R, Stern DF,. Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage response pathways. Mol Cancer Res. 2010; 8: 1388-1398.
49. Komuro A, Nagai M, Navin NE, Sudol M,. WW domain-containing protein YAP associates with ErbB-4 and acts as a cotranscriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem. 2003; 278: 33334-33341.
50. Sleeman JP, Nazarenko I, Thiele W,. Do all roads lead to Rome? Routes to metastasis development. Int J Cancer. 2011; 128: 2511-2526.
51. Ranganathan AC, Adam AP, Aguirre-Ghiso JA,. Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle. 2006; 5: 1799-1807.